TYPTF (Entropy Neurodynamics) Moat Score: 2/10 (As of Jun. 27, 2026)


What is Entropy Neurodynamics Moat Score?

Entropy Neurodynamics TYPTF -45.63% Moat Score is 2 as of Jun. 27, 2026. The stock has 5 warning signs investors should review. Among 1,404 Biotechnology companies, Entropy Neurodynamics ranks better than 58.12% on this metric.

Entropy Neurodynamics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Entropy Neurodynamics has No Moat: Entropy Neurodynamics Ltd lacks market leadership, customer loyalty, and significant intellectual property. The company does not have durable cost advantages or regulatory barriers, resulting in a very weak moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Entropy Neurodynamics might have No Moat - Very weak/transient advantages.

Entropy Neurodynamics  (OTCPK:TYPTF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Entropy Neurodynamics Moat Score Related Terms

TYPTF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Entropy Neurodynamics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entropy Neurodynamics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entropy Neurodynamics's Moat Score distribution charts can be found below:

* The bar in red indicates where Entropy Neurodynamics's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Entropy Neurodynamics (TYPTF) has a Moat Score of 2 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Entropy Neurodynamics ranks #588 out of 1404 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Entropy Neurodynamics' Moat Score too high?
Entropy Neurodynamics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Entropy Neurodynamics' value of 2 is 0% at this industry median. Based on the distribution chart, Entropy Neurodynamics ranks #588 out of 1404 companies in the Biotechnology industry, which is above the industry midpoint.
How does Entropy Neurodynamics' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Entropy Neurodynamics ranks #588 out of 1404 companies for Moat Score. This puts Entropy Neurodynamics in the upper half of its industry. The industry median Moat Score is 2.00. Entropy Neurodynamics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entropy Neurodynamics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entropy Neurodynamics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (TYPTF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 12% above its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Entropy Neurodynamics (TYPTF), the current Moat Score is 2 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entropy Neurodynamics Business Description

Other Exchanges ENP:Australia
Address 117 Camberwell Road,, Hawthorn East, Suite 1.01, Camberwell, Melbourne, VIC, AUS, 3123
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.